Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.66 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.66 |
| ▸ | CHRM3 | P20309 | 9/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 8/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 8/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1850881 | 1.00 | KEAP1 (0.66) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| SCHEMBL27422728 | 0.84 | KEAP1 (0.66) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| SCHEMBL4619902 | 0.83 | KEAP1 (0.68) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| SCHEMBL4618170 | 0.82 | KEAP1 (0.72) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| SCHEMBL360473 | 0.82 | KEAP1 (0.72) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| SCHEMBL1431227 | 0.82 | KEAP1 (0.72) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| SCHEMBL1235433 | 0.82 | KEAP1 (0.96) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| SCHEMBL198082 | 0.82 | KEAP1 (0.96) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| SCHEMBL2764243 | 0.82 | KEAP1 (0.96) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| SCHEMBL3909615 | 0.82 | KEAP1 (0.96) | KEAP1NFE2L2CHRM3CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110245293-A1 | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST | ASTRAZENECA AB (SE) | 2011-10-06 | — | — | US | disclosed |
| US-20110207770-A1 | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A SECOND ACTIVE INGREDIENT | ASTRAZENECA AB (SE) | 2011-08-25 | — | — | US | disclosed |
| EP-2323655-A1 | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A SECOND ACTIVE INGREDIENT | AstraZeneca AB (SE) | 2011-05-25 | — | — | EP | disclosed |
| EP-2323656-A1 | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST | AstraZeneca AB (SE) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010019097-A1 | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A SECOND ACTIVE INGREDIENT | ASTRAZENECA AB (SE) | 2010-02-18 | — | — | WO | disclosed |
| WO-2010018352-A1 | HETEROCYCLIC COMPOUNDS USED IN THE TREATMENT OF DISEASES WHERE ENHANCED M3 RECEPTOR ACTIVATION IS IMPLICATED | ARGENTA DISCOVERY LIMITED (GB) | 2010-02-18 | — | — | WO | disclosed |
| WO-2010019098-A1 | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST | ASTRAZENECA AB (SE) | 2010-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245293-A1 | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST | ADRB2, ADRB1, ADRA2A | KEAP1 1640/4885NFE2L2 1927/4885CHRM3 13/4885 |
| US-20110207770-A1 | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A SECOND ACTIVE INGREDIENT | GRK5, GRK2, GRK4 | KEAP1 3123/4885NFE2L2 4519/4885CHRM3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.